RPRX vs. BMY

Last updated Jun 4, 2026

RPRX (Royalty Pharma plc) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — RPRX in Biotechnology, BMY in Drug Manufacturers - General. Over the past 5 years, RPRX returned 6.45%/yr vs 0.60%/yr for BMY. At a 0.33 correlation, their price movements are largely independent.

Performance

RPRX vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Royalty Pharma plc (RPRX) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RPRX achieves a 43.64% return, which is significantly higher than BMY's 3.70% return.

RPRX

• 1D: 1.78%
• 1M: 9.99%
• YTD: 43.64%
• 6M: 40.16%
• 1Y: 68.67%
• 3Y*: 21.21%
• 5Y*: 6.45%
• 10Y*: —

BMY

• 1D: 0.48%
• 1M: -4.64%
• YTD: 3.70%
• 6M: 9.77%
• 1Y: 19.47%
• 3Y*: -1.44%
• 5Y*: 0.60%
• 10Y*: 0.60%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RPRX vs. BMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
RPRX Royalty Pharma plc	43.64%	55.29%	-6.36%	-27.08%	0.99%	-19.09%	13.33%
BMY Bristol-Myers Squibb Company	3.70%	0.11%	15.81%	-26.14%	18.98%	2.88%	11.24%

Correlation

The correlation between RPRX and BMY is 0.42, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.42
Correlation (3Y) Calculated over the trailing 3-year period	0.36
Correlation (5Y) Calculated over the trailing 5-year period	0.37
Correlation (All Time) Calculated using the full available price history since Jun 17, 2020	0.33

Fundamentals

EPS RPRX : $1.97 BMY : $3.57
PE Ratio RPRX : 27.92 BMY : 15.35
PEG Ratio RPRX : 0.03 BMY : 0.88
PS Ratio RPRX : 9.47 BMY : 2.30
Total Revenue (TTM) RPRX : $2.44B BMY : $48.48B
Gross Profit (TTM) RPRX : $1.81B BMY : $33.33B
EBITDA (TTM) RPRX : $1.70B BMY : $13.34B

Return for Risk

RPRX vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RPRX

RPRX Risk / Return Rank: 95
RPRX Sharpe Ratio Rank: 95
RPRX Sortino Ratio Rank: 94
RPRX Omega Ratio Rank: 94
RPRX Calmar Ratio Rank: 97
RPRX Martin Ratio Rank: 96

BMY

BMY Risk / Return Rank: 63
BMY Sharpe Ratio Rank: 64
BMY Sortino Ratio Rank: 59
BMY Omega Ratio Rank: 56
BMY Calmar Ratio Rank: 67
BMY Martin Ratio Rank: 67

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RPRX vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RPRX	BMY	Difference
Sharpe ratio Return per unit of total volatility	3.17	0.74	+2.44
Sortino ratio Return per unit of downside risk	3.94	1.25	+2.69
Omega ratio Gain probability vs. loss probability	1.53	1.15	+0.38
Calmar ratio Return relative to maximum drawdown	9.35	1.43	+7.92
Martin ratio Return relative to average drawdown	23.50	3.16	+20.34
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RPRX vs. BMY - Sharpe Ratio Comparison

The current RPRX Sharpe Ratio is 3.17, which is higher than the BMY Sharpe Ratio of 0.74. The chart below compares the historical Sharpe Ratios of RPRX and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	RPRX	BMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.17	0.74	+2.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.27	0.03	+0.25
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.02	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	0.34	-0.12

Drawdowns

RPRX vs. BMY - Drawdown Comparison

The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for RPRX and BMY.

Drawdown Indicators

	RPRX	BMY	Difference
Max Drawdown Largest peak-to-trough decline	-49.68%	-72.03%	+22.35%
Max Drawdown (1Y) Largest decline over 1 year	-7.38%	-13.68%	+6.30%
Max Drawdown (3Y) Largest decline over 3 years	-26.46%	-36.85%	+10.39%
Max Drawdown (5Y) Largest decline over 5 years	-43.44%	-47.67%	+4.23%
Max Drawdown (10Y) Largest decline over 10 years	—	-47.67%	—
Current Drawdown Current decline from peak	-1.42%	-21.26%	+19.84%
Average Drawdown Average peak-to-trough decline	-26.44%	-22.38%	-4.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.93%	6.17%	-3.24%

Volatility

RPRX vs. BMY - Volatility Comparison

Royalty Pharma plc (RPRX) and Bristol-Myers Squibb Company (BMY) have volatilities of 6.08% and 6.06%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RPRX	BMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.08%	6.06%	+0.02%
Volatility (6M) Calculated over the trailing 6-month period	14.04%	18.48%	-4.44%
Volatility (1Y) Calculated over the trailing 1-year period	21.75%	26.64%	-4.89%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.92%	23.98%	-0.06%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	26.87%	25.24%	+1.63%

Dividends

RPRX vs. BMY - Dividend Comparison

RPRX's dividend yield for the trailing twelve months is around 1.66%, less than BMY's 4.57% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BMY Bristol-Myers Squibb Company	4.57%	4.60%	4.24%	4.44%	3.00%	2.36%	3.69%	2.55%	3.08%	2.55%	1.95%	2.17%
RPRX Royalty Pharma plc	1.66%	2.28%	3.29%	2.85%	1.92%	1.71%	0.60%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

RPRX vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Royalty Pharma plc and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Royalty Pharma plc reported a gross profit of 0.00 and revenue of 631.00M. Therefore, the gross margin over that period was 0.0%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.

RPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Royalty Pharma plc reported an operating income of 563.00M and revenue of 631.00M, resulting in an operating margin of 89.2%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.

RPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Royalty Pharma plc reported a net income of 295.00M and revenue of 631.00M, resulting in a net margin of 46.8%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.

Frequently Asked Questions

Can I hold both RPRX and BMY in my portfolio?

RPRX and BMY have a correlation of 0.42, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RPRX or BMY?

RPRX has higher volatility (6.08%) compared to BMY (6.06%). In terms of maximum drawdown, RPRX dropped -49.68% vs BMY's -72.03%.

Which has better risk-adjusted returns?

RPRX currently has the higher Sharpe Ratio (3.17 vs 0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.